Arcus Biosciences(RCUS)
Focus: Arcus Biosciences is a publicly traded oncology-focused biotechnology company developing cancer immunotherapies, with a pipeline concentrated in checkpoint inhibitors and immuno-oncology combinations.
Profile data last refreshed 9h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Arcus Biosciences
AI assessmentNot HiringNo open roles listed right now. Follow Arcus Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Arcus Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$117M
Pipeline & Clinical Trials
Determination of Metal Ion Serum Levels and Cytokines in Total Hip Replacement
Hip Replacement ArthroplastyClinical Trials (1)
NCT01394744Determination of Metal Ion Serum Levels and Cytokines in Total Hip Replacement
N/AHelp build intelligence for Arcus Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.